Drug intelligence / Profile preview

talinolol

Development stage
Phase 1
Lead developer
Berlin-Chemie
Modality
Small Molecules
Administration
Oral
01

Overview

Talinolol is a long-acting, highly selective β1-adrenergic receptor antagonist (beta blocker) primarily used for the management of hypertension, angina pectoris, and various cardiac arrhythmias. By selectively blocking β1-adrenergic receptors in the heart, it reduces heart rate and contractility, delays AV node conduction, and diminishes the effects of catecholamines during physical or emotional stress. This results in decreased blood pressure and reduced frequency/severity of angina attacks. Talinolol has minimal activity at β2 receptors at therapeutic doses and lacks partial agonist activity or membrane-stabilizing effects. It is rapidly absorbed orally but has moderate bioavailability due to P-glycoprotein-mediated efflux; most of the drug is excreted unchanged in urine. Its half-life (~12 hours) allows for once-daily dosing. Talinolol also exhibits antioxidant properties and is sometimes used as a probe substrate for P-glycoprotein function in pharmacokinetic studies[1][5][6].

Brand names
Cordanum
Other names
talinololumracemic talinolol
02

Targets

ADRB1 (β1)

Beyond the preview

Go deeper on talinolol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on talinolol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call